PQB.F PURE BIOLOGICS ZY -10

Healthcare Biotechnology Frankfurt Exchange
0.2295 EUR
Close of Nov 12, 2026
0.2180 1.22
Market cap
EUR 51.8M
P/E
-
P/B
1.52x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is PQB.F undervalued?

Graham number

The Graham number of PURE BIOLOGICS ZY -10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PURE BIOLOGICS ZY -10 fundamental analysis

No fundamental analysis for PURE BIOLOGICS ZY -10 yet.

PURE BIOLOGICS ZY -10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PURE BIOLOGICS ZY -10

MultiQure S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was formerly known as Pure Biologics S.A. and changed its name to MultiQure S.A. in August 2026.…

Full company profile